Simdax
(levosimendan)Phase 3Small molecule
Orion Corporation, Orion PharmaLevosimendan is used to treat acute heart failure in patients with reduced heart function, helping the heart pump blood more effectively and improving symptoms like shortness of breath and fatigue.[1] Simdax is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Simdax is one of 189 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
6
Indications
81
Total Trials
3
Active Trials
188
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
198 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Simdax
Orion Corporation, Orion PharmaPhase 3
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Zemplar
AbbViePreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Oraverse
LLife Extension Foundation Inc.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Tamiflu
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Heart Failure17 trials
Show 14 more trials
Levosimendan in Acute Decompensated Heart Failure
Not yet recruiting·—·Phase 2/3·NCT07262723·332 enrolled
Interest of Levosimendan Preconditioning for Cardiac Surgery Under CEC in Heart Failure Patients With Impaired Ejection Fraction
Unknown status·—··NCT06021587·300 enrolled
Cardiac Surgery4 trials
Levosimendan in Congenital Cardiac Surgery
Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·N/A·NCT00695929·50 enrolled
Levosimendan Administration and Outcome in Cardiac Surgery
Completed·—··NCT02275013·159 enrolled
Surgery4 trials
Two Inodilators Postsurgery in Neonates
Completed·FFundacion para la Investigacion Biomedica del Hospital Universitario la Paz·Phase 1/2·NCT01576094·20 enrolled
Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery
Completed·—·Phase 4·NCT01318460·32 enrolled
Show 1 more trial
Levosimendan Versus Milrinone in Off Pump CABG Surgery
Unknown status·—·Phase 4·NCT03855579·60 enrolled
Septic Shock3 trials
46 more indications
Function2 trials
Cardiac2 trials
Efficacy2 trials
Myocardial Infarction1 trial
Acute Myocardial Infarction1 trial
Amyotrophic Lateral Sclerosis1 trial
Concentration1 trial
Mechanically Ventilated Patients1 trial
Systolic Heart Failure1 trial
Ventricular Function1 trial
Levosimendan in Patients With Impaired Right Ventricular Function Undergoing Cardiac Surgery
Unknown status·—·Phase 2·NCT05063370·40 enrolled
Transposition of the Great Arteries1 trial
Levosimendan Administration in Neonates With Transposition of the Great Arteries
Completed·—·Phase 2·NCT01120106·63 enrolled
After Cardiac Surgery1 trial
Impact of Levosimendan Preconditioning on Critical Care and In-hospital Lengths of Stay After Cardiac Surgery With Bypass Surgery
Unknown status·—··NCT05685537·120 enrolled
Postoperative Cardiac Surgery1 trial
Abdominal Cancer Surgeries1 trial
Coronary Artery Bypass1 trial
Mitral Valve Surgery1 trial
The Effects of Levosimendan During Mitral Valve Surgery
Completed·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·Phase 4·NCT01969071·140 enrolled
Cardiopulmonary Bypass1 trial
CABG1 trial
Comparison Between Levosimendan and Adrenaline in CABG Patients
Unknown status·—·N/A·NCT05222256·52 enrolled
Aortic Stenosis1 trial
Critically Ill Patients1 trial
Left Ventricular Hypertrophy1 trial
Infants1 trial
Clinical Trial1 trial
Right Ventricular Dysfunction1 trial
Left Ventricular Systolic Dysfunction1 trial
ARDS1 trial
Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2/3·NCT05768230·58 enrolled
Cardiogenic Shock1 trial
Congenital Heart Disease1 trial
Open Heart Surgery1 trial
Acute Decompensated Heart Failure (ADHF)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for levosimendan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details